CytRx to Present at Rodman & Renshaw 12th Annual Healthcare Conference

Published on Wednesday, 08 September 2010 08:33 Written by TradersHuddle Staff

LOS ANGELES-( Business Wire )-

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.D., will be presenting at the 12^th Annual Rodman & Renshaw Healthcare Conference on Tuesday, September 14, at 9:35 a.m. Eastern time (6:35 a.m. Pacific time). The conference is being held at the New York Palace Hotel.

The CytRx presentation will address actions to advance the clinical development of the Company’s high-value oncology development pipeline, including a discussion of the recently initiated Phase 2 clinical trials to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer and high-risk B-cell chronic lymphocytic leukemia, and plans to initiate up to four additional oncology clinical trials.

A live webcast of the presentation will be available at http://www.cytrx.com and a webcast replay will be archived on the Company's website for 90 days.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: bafetinib, tamibarotene and INNO-206. The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL) and the PROACT Phase 2 clinical trial in advanced prostate cancer, and plans to begin a Phase 1 trial in brain cancer. CytRx has announced plans to initiate up to three Phase 2 clinical trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas. In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 17% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit http://www.cytrx.com.

Investor RelationsLegend Securities, Inc.Thomas Wagner800-385-5790 x152718-233-2600 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.